The Fund Grade · free · no account needed
What grade does BPIRX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Boston Partners Long/Short Research Fund
#470 of 500 graded active funds · blend · large segment peer group
The point · specialist footprint
BPIRX puts less of its book behind proven specialists than 65% of graded funds.
Bottom 20%
● Bottom 40%
Middle
Top 40%
Top 20%
That has mattered: over the past 2.7 years, funds with this little specialist backing trailed top-rung funds by about 3.8% per quarter and beat the S&P in only 22% of fund-quarters. If it also charges an active fee, the higher-graded alternatives deserve a look.
10,000+ funds tracked · the graded specialists among them drive every read
3 funds in the same segment carry an A. Members see the names and what they charge. See the alternatives →
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
BPIRX vs the Honor Roll · share card ↗Conviction exposure
16.3%
of the book in specialist-converged names
Late-stage weight
28.6%
of the book in Crowded or Fading names
Active share
87.4%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
Boston Partners Long/Short Research Fund grades F, ranking 470 of 500, with only 16.3% specialist backing. Specialists are actively leaving positions like AVGO, NI, and BCO, while nearly 29% of the portfolio sits in late-stage trades. STX, ABBV, and BAC show some early conviction, but higher-graded peers and better options within the same fund family exist.
→ Watch AVGO, NI, and BCO closely, as specialist managers are fading all three positions simultaneously.
→ Compare this fund against the three higher-graded peers in its segment before holding further.
Support leaving these positions
Same family, higher grade
Read from today's disclosed book. Evidence, not advice.